DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tenapanor
Tenapanor
Review Article: Diagnosis, Management and Patient Perspectives of the Spectrum of Constipation Disorders
Chronic Constipation: Update on Management
Relative Efficacy of Tegaserod in a Systematic Review and Network Meta-Analysis of Licensed Therapies for Irritable Bowel Syndrome with Constipation
Efficacy and Safety of Intestinal Secretagogues for Chronic Constipation: a Systematic Review and Meta-Analysis
Multi-Discipline Review
The Pathogenic Roles and Gastrointestinal Decontamination of Uremic Toxins
Ibsrela (Tenapanor)
Chronic Constipation in Adults: Contemporary Perspectives and Clinical Challenges. 2: Conservative, Behavioural, Medical and Surgical Treatment
Constipation Agents
NH Medicaid FFS Drugs for Bowel Disorders/GI Motility, Chronic Criteria
RISK ASSESSMENT and RISK MITIGATION REVIEW(S)
Inhibition of Sodium/Hydrogen Exchanger 3 in the Gastrointestinal Tract by Tenapanor Reduces Paracellular Phosphate Permeability
The Management of Adult Patients with Severe Chronic Small Intestinal Dysmotility Gut: First Published As 10.1136/Gutjnl-2020-321631 on 21 August 2020
Efficacy of Drugs in Chronic Idiopathic Constipation: a Systematic Review and Network Meta-Analysis
Tenapanor: New Approach to Counter Irritable Bowel Syndrome with Constipation
Drugs for Constipation Reference Number: TCHP.PHAR.185 Effective Date: 07.01.18 Last Review Date: 04.15.21 Line of Business: Oregon Health Plan, Medicaid Revision Log
Tenapanor (Ibsrela) Reference Number: CP.PMN.224 Effective Date: 03.01.20 Last Review Date: 02.20 Line of Business: Commercial, HIM, Medicaid Revision Log
Tenapanor) Tablets, for Oral Use ------DOSAGE FORMS and STRENGTHS------ Initial U.S
Top View
Tenapanor for Irritable Bowel Syndrome with Constipation NIHRIO (HSRIC) ID: 6704 NICE ID: 9736
Drug Class Update: Laxatives for Chronic Constipation
WO 2018/129552 Al 12 July 2018 (12.07.2018) W !P O PCT
Up-To-Date Diagnosis and Management of IBS and Chronic Constipation in Primary Care
ARDELYX, INC. Fremont, CA 94555 34175 Ardenwood Blvd
Ibsrela (Tenapanor)
Efficacy of Secretagogues in Patients with Irritable Bowel Syndrome with Constipation: Systematic Review and Network Meta-Analysis
Tenapanor Treatment of Patients with Constipation-Predominant Irritable Bowel Syndrome: a Phase 2, Randomized, Placebo-Controlled Effi Cacy and Safety Trial
Medication Coverage Policy
Pre - PA Allowance None ______
New Drug Evaluation Monograph Template
Tenapanor (Ibsrela®) EOCCO POLICY
CHRONIC CONSTIPATION Western Management Perspective 2015
Clinically Preferred Drug List 2Nd Quarter Edition
WHO Drug Information Contents
Guidelines for ATC Classification and DDD Assignment 2021
Ibsrela (Tenapanor), Trulance (Plecanatide), Zelnorm (Tegaserod) P&T Approval Date 6/2017, 3/2018, 3/2019, 12/2019 Effective Date 3/1/2020; Oxford Only: 3/1/2020
Irritable Bowel Syndrome and Constipation Agents
Pharmacy Medical Necessity Guidelines: Gastrointestinal Medications
Evaluation and Management of Chronic Constipation
ATC Vet 2021 Atccode Atcdescription Atcdescriptionsi QA ALIMENTARY TRACT and METABOLISM ZDRAVILA ZA BOLEZNI PREBAVIL in PRESNOVE
5.01.605 Medical Necessity Criteria for Pharmacy Edits
Molecular Basis and Differentiation-Associated Alterations of Anion Secretion in Human Duodenal Enteroid Monolayers
Current Overview on Clinical Management of Chronic Constipation
Constipation Agents- ARIZONA